UCB's Neupro available again in the EU
This article was originally published in Scrip
UCB is making available again its transdermal patch, Neupro (rotigotine), in the EU, following approval by the European Commission of last month's positive opinion from the CHMP (scripnews.com, June 1st, 2009). It is indicated for the treatment of Parkinson's disease and a new indication, restless legs syndrome.
You may also be interested in...
Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.